Fiche centre
Hôpital Pasteur
Nice — France
Essais liés9clinical trials
VilleNicelocalisation
PaysFrancelocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06675955
Essais cliniques associés
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ocrelizumab | SEP | Phase 3 | NCT06675955 | OleroMAX — An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment | RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT03599245 | This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) | COMPLETED |
| RESPONSE — French Registry for Monitoring Pregnancies for Multiple Sclerosis | SEP | À vérifier | NCT03900221 | RESPONSE — French Registry for Monitoring Pregnancies for Multiple Sclerosis | RECRUITING |
| Vicadrostat | Hypertension | Phase 3 | NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | RECRUITING |
| Telitacicept | Myasthénie | Phase 3 | NCT06456580 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | ACTIVE_NOT_RECRUITING |
| EGb 761® (Tanakan®) | Alzheimer | Phase 4 | NCT00276510 | A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints | COMPLETED |
| Ponesimod | SEP | Phase 3 | NCT03232073 | Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis | COMPLETED |
| Fenebrutinib | SEP | Phase 3 | NCT04586023 | FENhance 2 — Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |